A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Although outcomes for patients with multiple myeloma have improved, it remains an incurable malignancy for which new therapies are needed. At a cellular level the Aurora kinases regulate mitotic di...